Aceclofenac is a popular analgesic, antipyretic and nonsteroidal anti-inflammatory drug (NSAID) used for prolonged treatment (at least three months) in musculoskeletal disorders. It is characterized by several limitations, such as poor water solubility and low oral bioavailability. The main side-effect of aceclofenac, as well as all NSAIDs, is the gastrotoxicity; among other adverse effects, there is the risk of bleeding since aceclofenac reversibly inhibits platelet aggregation. With the aim to reduce these drawbacks, we have designed, synthesized and characterized both in vitro and in vivo, an orally administrable pro-drug of aceclofenac (ACEgal). ACEgal was obtained by conjugating carboxyl group with the 6-OH group of D-galactose; its structure was confirmed by X-ray powder diffractometry. The pro-drug was shown to be stable at 37°C in simulated gastric fluid (SGF-without pepsin, pH=1.2), and moderately stable in phosphate buffered saline (PBS, pH=7.4). However, it hydrolyzed in human serum with a half-life (t1/2) of 36 minutes, producing aceclofenac. Furthermore, if compared to its parent drug, ACEgal was four times more soluble in SGF. In order to predict human intestinal absorption, cell permeability in a Caco-2 model of aceclofenac and ACEgal was determined. Anti-inflammatory, analgesic, and ulcerogenic activities have been investigated in vivo. In addition, oxidative stress parameters (thiobarbituric acid reactive substances, TBARS and glutathione, GSH) and platelet anti-aggregatory activity both of parent drug and pro-drug were evaluated. Results clearly showed that the conjugation of aceclofenac to a galactose molecule improves physico-chemical, toxicological (at gastric and blood level) and pharmacological profile of aceclofenac itself, without changing intestinal permeability and anti-platelet activity (in spite the new sugar moiety).

Aceclofenac-galactose conjugate: design, synthesis, characterization and pharmacological and toxicological evaluations

Lazzarato, Loretta;Rolando, Barbara;Chegaev, Konstantin;Marini, Elisabetta;Marabello, Domenica;Gazzano, Elena;Riganti, Chiara;Sodano, Federica;
2018

Abstract

Aceclofenac is a popular analgesic, antipyretic and nonsteroidal anti-inflammatory drug (NSAID) used for prolonged treatment (at least three months) in musculoskeletal disorders. It is characterized by several limitations, such as poor water solubility and low oral bioavailability. The main side-effect of aceclofenac, as well as all NSAIDs, is the gastrotoxicity; among other adverse effects, there is the risk of bleeding since aceclofenac reversibly inhibits platelet aggregation. With the aim to reduce these drawbacks, we have designed, synthesized and characterized both in vitro and in vivo, an orally administrable pro-drug of aceclofenac (ACEgal). ACEgal was obtained by conjugating carboxyl group with the 6-OH group of D-galactose; its structure was confirmed by X-ray powder diffractometry. The pro-drug was shown to be stable at 37°C in simulated gastric fluid (SGF-without pepsin, pH=1.2), and moderately stable in phosphate buffered saline (PBS, pH=7.4). However, it hydrolyzed in human serum with a half-life (t1/2) of 36 minutes, producing aceclofenac. Furthermore, if compared to its parent drug, ACEgal was four times more soluble in SGF. In order to predict human intestinal absorption, cell permeability in a Caco-2 model of aceclofenac and ACEgal was determined. Anti-inflammatory, analgesic, and ulcerogenic activities have been investigated in vivo. In addition, oxidative stress parameters (thiobarbituric acid reactive substances, TBARS and glutathione, GSH) and platelet anti-aggregatory activity both of parent drug and pro-drug were evaluated. Results clearly showed that the conjugation of aceclofenac to a galactose molecule improves physico-chemical, toxicological (at gastric and blood level) and pharmacological profile of aceclofenac itself, without changing intestinal permeability and anti-platelet activity (in spite the new sugar moiety).
15
8
3101
3110
Aceclofenac; non steroidal anti-inflammatory drug; pharmacology; toxicology
Magliocca, Salvatore; De Caro, Carmen; Lazzarato, Loretta; Russo, Roberto; Rolando, Barbara; Chegaev, Konstantin; Marini, Elisabetta; Nieddu, Maria; Burrai, Lucia; Boatto, Gianpiero; Cristiano, Claudia; Marabello, Domenica; Gazzano, Elena; Riganti, Chiara; Sodano, Federica; Rimoli, Maria Grazia
File in questo prodotto:
File Dimensione Formato  
Magliocca, Mol Pharm, 2018.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.63 MB
Formato Adobe PDF
1.63 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Magliocca per Open Access.docx

Accesso riservato

Descrizione: Magliocca, Opena Access con embargo, 2018
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 1.14 MB
Formato Microsoft Word XML
1.14 MB Microsoft Word XML   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1670027
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact